验证脑损伤指南:美国创伤外科协会前瞻性多中心试验结果
本研究为前瞻性、观察性、多中心试验,在美国九家一级和二级创伤中心纳入2,432例16岁及以上、初始头颅CT阳性的钝性TBI患者,按神经系统检查、酒精中毒、抗血小板/抗凝药物使用和头颅CT表现分为BIG 1、2、3。BIG 1患者无临床恶化、无需神经外科干预;BIG 2患者中0.7%临床恶化、7.1%复查CT进展,但无需神经外科干预;所有需神经外科干预者均为BIG 3(19.5%)。实施BIG可使CT使用和神经外科会诊总体减少29%,BIG 1减少100%、BIG 2减少98%。结论认为BIG安全,创伤与急重症外科医生可据此管理TBI患者而无需常规复查头颅CT和神经外科会诊。
要点
- BIG 1患者(301例,14.8%)无临床恶化,4例(1.3%)复查头颅CT进展但无需改变管理,无需神经外科干预。
- BIG 2患者(295例,14.5%)中2例(0.7%)临床恶化,21例(7.1%)复查CT进展,7例(2.4%)需升级至BIG 3,但无需神经外科干预。
- 所有需神经外科干预的患者均为BIG 3(280/1,437,19.5%)。
- 实施BIG可使CT使用和神经外科会诊总体减少29%,BIG 1减少100%、BIG 2减少98%。
- BIG 1和2患者无TBI相关出院后急诊就诊或30天再入院。
适用人群与场景
- 成人(16岁及以上)钝性TBI患者,初始头颅CT扫描阳性,来自九家一级和二级创伤中心。
诊断标准与关键阈值
- 根据神经系统检查、酒精中毒、抗血小板/抗凝药物使用和头颅CT表现将患者分为BIG 1、2、3。
处置流程与药物剂量
- BIG 1和BIG 2患者无需常规复查头颅CT和神经外科会诊;BIG 3患者需神经外科干预。
红旗征与不能漏的情况
- BIG 1患者若出现临床恶化或复查CT进展需考虑升级管理;BIG 2患者若出现神经系统检查恶化或复查CT进展需升级至BIG 3。
研究设计与关键结果
- 前瞻性、观察性、多中心试验,九家一级和二级创伤中心,2,432例符合纳入标准,2,033例无缺失信息并分为BIG 1(301例,14.8%)、BIG 2(295例,14.5%)、BIG 3(1,437例,70.7%)。
- BIG 1:无临床恶化,4/301(1.3%)复查CT进展但无需改变管理,无需神经外科干预。
- BIG 2:2/295(0.7%)临床恶化,21/295(7.1%)复查CT进展,7/295(2.4%)需升级至BIG 3,无需神经外科干预。
- BIG 1和2患者无TBI相关出院后急诊就诊或30天再入院。
- 所有需神经外科干预者均为BIG 3(280/1,437,19.5%)。
- 分配与最终BIG分类一致性极好(κ=99%)。
- 实施BIG可使CT使用和神经外科会诊总体减少29%,BIG 1减少100%,BIG 2减少98%。
证据类型、等级与局限
- 证据类型:前瞻性、观察性、多中心试验;证据等级:治疗/护理管理;Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为BIG安全,创伤与急重症外科医生可据此管理TBI患者而无需常规复查头颅CT和神经外科会诊。
指南或共识出处
- 脑损伤指南(Brain Injury Guidelines, BIG);美国创伤外科协会(American Association for the Surgery of Trauma)前瞻性多中心试验。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Brain Injury Guidelines (BIG) was developed to effectively use health care resources including repeat head computed tomography (RHCT) scan and neurosurgical consultation in traumatic brain injury (TBI) patients. The aim of this study was to prospectively validate BIG at a multi-institutional level.
METHODS: This is a prospective, observational, multi-institutional trial across nine Levels I and II trauma centers. Adult (16 years or older) blunt TBI patients with a positive initial head computed tomography (CT) scan were identified and categorized into BIG 1, 2, and 3 based on their neurologic examination, alcohol intoxication, antiplatelet/anticoagulant use, and head CT scan findings. The primary outcome was neurosurgical intervention. The secondary outcomes were neurologic worsening, RHCT progression, postdischarge emergency department visit, and 30-day readmission.
RESULTS: A total of 2,432 patients met the inclusion criteria, of which 2,033 had no missing information and were categorized into BIG 1 (301 [14.8%]), BIG 2 (295 [14.5%]), and BIG 3 (1,437 [70.7%]). In BIG 1, no patient worsened clinically, 4 of 301 patients (1.3%) had progression on RHCT with no change in management, and none required neurosurgical intervention. In BIG 2, 2 of 295 patients (0.7%) worsened clinically, and 21 of 295 patients (7.1%) had progression on RHCT. Overall, 7 of 295 patients (2.4%) would have required upgrade from BIG 2 to 3 because of neurologic examination worsening or progression on RHCT, but no patient required neurosurgical intervention. There were no TBI-related postdischarge emergency department visits or 30-day readmissions in BIG 1 and 2 patients. All patients who required neurosurgical intervention were BIG 3 (280 of 1,437 patients [19.5%]). Agreement between assigned and final BIG categories was excellent ( κ = 99%). In this cohort, implementing BIG would have decreased CT scan utilization and neurosurgical consultation by 29% overall, with a 100% reduction in BIG 1 patients and a 98% reduction in BIG 2 patients.
CONCLUSION: Brain Injury Guidelines is safe and defines the management of TBI patients by trauma and acute care surgeons without the routine need for RHCT and neurosurgical consultation.
LEVEL OF EVIDENCE: Therapeutic/Care Management; Level III.
参考来源
- Joseph B, Obaid O, Dultz L, et al. Validating the Brain Injury Guidelines: Results of an American Association for the Surgery of Trauma prospective multi-institutional trial. J Trauma Acute Care Surg. 2022. PMID: 35343931. doi:10.1097/TA.0000000000003554
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。